- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04253314
A Study of the Effectiveness of Venetoclax Tablets in Adult Acute Myeloid Leukemia Participants Ineligible for Standard Induction Therapy in Russian Federation (INNOVATE)
Prospective Multi-Center Observational Study to Assess Effectiveness of Venclexta (Venetoclax) in Acute Myeloid Leukemia (AML) Patients Ineligible for Standard Induction Therapy in Routine Clinical Practice in Russian Federation (INNOVATE)
Acute Myeloid Leukemia (AML) is a cancer of the blood and bone marrow and is the most common acute leukemia in adults. This study will evaluate how well Venetoclax works to treat AML in adult participants who are ineligible for standard induction therapy in Russian Federation.
Venetoclax is a drug approved to treat Acute Myeloid Leukemia. All study participants will receive Venetoclax as prescribed by their study doctor in accordance with approved local label. Adult participants with a diagnosis of AML who are ineligible for standard induction therapy will be enrolled. Around 50 participants will be enrolled in the study in approximately 15 sites in Russian Federation.
Participants will receive venetoclax tablets to be taken by mouth daily according to the approved local label. The duration of the study is approximately 18 months.
There is expected to be no additional burden for participants in this trial. All study visits will occur during routine clinical practice (approximately every 3 months) and participants will be followed for 18 months.
Study Overview
Status
Conditions
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Irkutsk, Russian Federation, 664049
- Regional Clinical Hospital of Irkutsk /ID# 218570
-
Perm, Russian Federation, 614077
- Clinical Medico-Sanitary Unit #1 /ID# 222502
-
Sankt-Peterburg, Russian Federation, 191024
- Russian Research Institute of Hematology and Transfusiology of the FMBA /ID# 229812
-
Sankt-Peterburg, Russian Federation, 197341
- Almazov National Medical Research Centre /ID# 218571
-
St. Petersburg, Russian Federation, 197101
- R.M.Gorbacheva Research Institute of Paediatric Oncology, Haematology and Transp /ID# 224831
-
Yakutsk, Russian Federation, 677008
- Republican Hospital #1 - National Center of Medicine of Sakha (Yakutia) /ID# 224830
-
Yuzhno-Sakhalinsk, Russian Federation, 693004
- Sakhalin Regional Clinical Hospital /ID# 222501
-
-
Moskva
-
Moscow, Moskva, Russian Federation, 125284
- Moscow State budget healthcare /ID# 218569
-
-
Saratovskaya Oblast
-
Saratov, Saratovskaya Oblast, Russian Federation, 410012
- Saratov State Medical University n.a. V.I. Razumovskiy /ID# 226059
-
-
Volgogradskaya Oblast
-
Volgograd, Volgogradskaya Oblast, Russian Federation, 400138
- Hematology department State budgetary health care institution Volgograd region /ID# 229813
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Newly diagnosed acute myeloid leukemia (AML) (de novo or secondary) and eligible to receive Venetoclax as per Russian Ministry of Health label
- Ineligible for standard induction therapy with cytarabine and anthracycline
- Eastern Cooperative Oncology Group (ECOG) score >2
- White blood cell counts <25 x 109 per liter
- Started Venetoclax within 4 weeks of enrolling in study
Exclusion Criteria:
- Acute promyelocytic leukemia
- Contraindications to Venetoclax as listed on the approved local label in Russian Federation
- Neuroleukemia - active central nervous system (CNS) involvement
- Participation in a clinical trial with an investigational drug for AML within 30 days prior to Venetoclax treatment initiation
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
---|
Venetoclax Participants
Participants treated with Venetoclax in accordance with approved local label.
Decision to treat with Venetoclax was made prior to offering participation in this study.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall Survival
Time Frame: Approximately 18 months
|
Defined as the time (in days) between the date of first Venetoclax intake to date of death.
|
Approximately 18 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall Response Rate
Time Frame: Approximately 18 months
|
Defined as the percentage of participants with either complete response (CR) or complete response with incomplete hematological recovery (CRi) according to physician's assessment.
|
Approximately 18 months
|
Best Overall Response Rate
Time Frame: Approximately 18 months
|
Defined as the percentage of participants with either CR or CRi according to physician's assessment during Venetoclax treatment.
|
Approximately 18 months
|
Best complete Remission
Time Frame: Approximately 18 months
|
Defined as the percentage of participants with CR according to physician's assessment during Venetoclax treatment.
|
Approximately 18 months
|
Time to First Response
Time Frame: Approximately 18 months
|
Defined as the time (in weeks) between the date of first Venetoclax intake to first response, among CR, CRi, and morphologic leukemia free state (MLSF).
|
Approximately 18 months
|
Time to Best Response to Treatment
Time Frame: Approximately 18 months
|
Defined as the time (in weeks) between the date of first Venetoclax intake and the date of hte assessment having documented the best response among CR, CRi, and MLSF.
|
Approximately 18 months
|
Duration of Response (DOR)
Time Frame: Approximately 18 months
|
Defined as the time (in weeks) between the date of the first assessment documenting the response to Venetoclax (either CR, CRi, or MLSF) and the date of the first assessment having documented the progression.
|
Approximately 18 months
|
Event-Free Survival (EFS)
Time Frame: Approximately 18 months
|
Defined as the time (in weeks) between the date of first Venetoclax intake and the date of the first assessment having documented disease progression (primary refractory disease, or relapse from CR, CRi, or death from any cause).
|
Approximately 18 months
|
Relapse-Free Survival (RFS)
Time Frame: Approximately 18 months
|
Defined as the time between the date of CR and the date of the first assessment having documented disease progression or death from any cause.
|
Approximately 18 months
|
Time to Transfusion Independence
Time Frame: Approximately 18 months
|
Defined as the time (in weeks) between the date of first Venetoclax intake and the absence of any red blood cell (RBC) or platelet transfusion during any consecutive 8 weeks during the treatment period.
|
Approximately 18 months
|
Percentage of participants treated with Venetoclax in combination with hypomethylating agents (HMAs)
Time Frame: Approximately 18 months
|
Defined as the percentage of participants treated with Venetoclax in combination with hypomethylating agents (HMAs).
|
Approximately 18 months
|
Percentage of participants treated with Venetoclax in combination with low dose cytarabine (LDAC)
Time Frame: Approximately 18 months
|
Defined as the percentage of participants treated with Venetoclax in combination with low dose cytarabine (LDAC).
|
Approximately 18 months
|
Percentage of participants treated with Venetoclax in combination with other therapeutic agents
Time Frame: Approximately 18 months
|
Defined as the percentage of participants treated with Venetoclax in combination with other therapeutic agents
|
Approximately 18 months
|
Percentage of participants with dose modifications
Time Frame: Approximately 18 months
|
Percentage of participants with dose modifications.
|
Approximately 18 months
|
Percentage of participants with dose interruptions
Time Frame: Approximately 18 months
|
Percentage of participants with dose interruptions
|
Approximately 18 months
|
Percentage of participants taking concimtant CYP3A medications
Time Frame: Approximately 18 months
|
Percentage of participants taking concimtant CYP3A medications while treated with Venetoclax.
|
Approximately 18 months
|
Number of participants with adverse events
Time Frame: Approximately 18 months
|
An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment.
The investigator assesses the relationship of each event to the use of study drug as either probably related, possibly related, probably not related or not related.
A serious adverse event (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above.
Treatment-emergent adverse events/treatment-emergent serious adverse events (TEAEs/TESAEs) are defined as any event that began or worsened in severity after the first dose of study drug.
|
Approximately 18 months
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- P20-147
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Myeloid Leukemia (AML)
-
Goethe UniversityCompleted
-
Daiichi Sankyo, Inc.CompletedAMLUnited States, Korea, Republic of, Taiwan, United Kingdom, France, Australia, Spain, Italy, Canada, Singapore, Germany, Netherlands, Hong Kong, Belgium, Croatia, Czechia, Hungary, Poland, Serbia
-
Gemin XCompleted
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.RecruitingNewly Diagnosed Acute Myeloid Leukemia (AML)China
-
Zhejiang ACEA Pharmaceutical Co. Ltd.Recruiting
-
German Cancer Research CenterUniversity Hospital Heidelberg; University Hospital DresdenNot yet recruitingRelapsed/Refractory Acute Myeloid Leukemia (AML)Germany
-
Georgetown UniversityNational Heart, Lung, and Blood Institute (NHLBI); Jazz PharmaceuticalsRecruitingAcute Myeloid Leukemia (AML) in RemissionUnited States
-
Tarapeutics Science Inc.RecruitingRelapsed or Refractory Acute Myeloid Leukemia (AML)China
-
Tarapeutics Science Inc.RecruitingRelapsed or Refractory Acute Myeloid Leukemia (AML)China
-
The First Affiliated Hospital of Xiamen UniversityFujian Cancer Hospital; Huizhou Municipal Central Hospital; Chipscreen Biosciences... and other collaboratorsRecruitingLeukemia, Myeloid, Acute | AML Stage, AdultChina